Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Conditions
Interventions
Belumosudil (KD025)
Placebo
Locations
26
United States
Viable Research Management_Site number 131
Phoenix, Arizona, United States
Mayo Clinic - Scottsdale_Site number 150
Scottsdale, Arizona, United States
University of California, SD_Site number 008
La Jolla, California, United States
Pacific Arthrirtis Care Center_Site number 136
Los Angeles, California, United States
University of California - Los Angeles_Site number 104
Los Angeles, California, United States
Stanford University Medical Center_Site number 143
Palo Alto, California, United States
Start Date
June 26, 2019
Primary Completion Date
August 9, 2022
Completion Date
February 17, 2023
Last Updated
August 30, 2023
NCT05270668
NCT05626751
NCT04986605
NCT04478994
NCT03198689
NCT05080738
Lead Sponsor
Kadmon, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions